NHAS
MPLT

Novo Holdings A/S’s MapLight Therapeutics MPLT Stock Holding History

Novo Holdings A/S’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$74.9M Hold
3,686,622
– – 6.07% 5
2025
Q4 		$64.8M Buy
+3,686,622
New +$61.8M 5.03% 8

Other funds holding MPLT

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Novo Holdings A/S's MPLT Position: Q1 2026 in Review

Novo Holdings A/S held its MapLight Therapeutics (MPLT) position steady in Q1 2026 at 3,686,622 shares worth $74.9M. The position accounts for 6.07% of the portfolio, ranked #5.

Novo Holdings A/S first reported a position in MPLT in Q4 2025 and has held it in 2 quarters since. 81 funds tracked by Wall St. Rank hold MPLT as of Q1 2026.

  • Novo Holdings A/S held 3,686,622 shares of MapLight Therapeutics worth $74.9M as of Q1 2026.
  • Novo Holdings A/S left its MapLight Therapeutics share count unchanged in Q1 2026.
  • MapLight Therapeutics made up 6.07% of Novo Holdings A/S's portfolio in Q1 2026, its #5 holding.
  • Novo Holdings A/S first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 81 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q1 2026.

Based on Novo Holdings A/S's 13F filing for Q1 2026, filed 15 May 2026.